Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2B | O00750 | 19/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.54 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17166189 | 0.90 | PIK3C2B (0.81) | PIK3C2BPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL1281411 | 0.89 | PIK3C2B (1.00) | PIK3C2BPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1282281 | 0.88 | PIK3C2B (0.78) | PIK3C2BPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL15022730 | 0.88 | PIK3C2B (0.81) | PIK3C2BPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL1281001 | 0.88 | PIK3C2B (1.00) | PIK3C2BPIK3CDPIK3CBPIK3R1 | |
| SCHEMBL1281608 | 0.88 | PIK3C2B (0.78) | PIK3C2BPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL1280582 | 0.88 | PIK3C2B (0.81) | PIK3C2BPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL27903800 | 0.86 | PIK3C2B (0.75) | PIK3C2BPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL1280830 | 0.85 | PIK3C2B (0.75) | PIK3C2BPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL1688063 | 0.85 | PIK3C2B (0.74) | PIK3C2BPIK3CDPIK3CBPIK3R1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3170813-B1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2018-12-12 | — | — | EP | claimed |
| EP-3170813-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | Glaxosmithkline LLC (US) | 2017-05-24 | — | — | EP | claimed |
| US-8435988-B2 | Benzimidazole derivatives as P13 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-05-07 | — | — | US | claimed |
| US-20120088767-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-04-12 | — | — | US | claimed |
| US-10660898-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-26 | — | — | US | disclosed |
| US-10660898-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190255064-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2019-08-22 | — | — | US | disclosed |
| US-20190255064-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2019-08-22 | — | — | US | disclosed |
| US-10314845-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-06-11 | — | — | US | disclosed |
| US-10314845-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3170813-B1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-20180263994-A1 | Benzimidazole Derivatives as PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2018-09-20 | — | — | US | disclosed |
| US-20130196990-A1 | Benzimidazole Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2013-08-01 | — | — | US | disclosed |
| US-8435988-B2 | Benzimidazole derivatives as P13 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435988-B2 | Benzimidazole derivatives as P13 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435988-B2 | Benzimidazole derivatives as P13 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120088767-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-04-12 | — | — | US | disclosed |
| WO-2012047538-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-04-12 | — | — | WO | disclosed |
| US-20120088767-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-04-12 | — | — | US | disclosed |
| US-20120088767-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263994-A1 | Benzimidazole Derivatives as PI3 Kinase Inhibitors | PI4KB, PIK3CD, PI4KA | PIK3C2B 13/4885PIK3CD 2/4885PIK3CB 4/4885 |
| US-20120088767-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | PI4KB, PI4KA, PIK3CD | PIK3C2B 13/4885PIK3CD 3/4885PIK3CB 4/4885 |
| US-10660898-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | PI4KB, PIK3CD, PI4KA | PIK3C2B 13/4885PIK3CD 2/4885PIK3CB 4/4885 |
| US-20130196990-A1 | Benzimidazole Derivatives As PI3 Kinase Inhibitors | PI4KB, PIK3CD, PI4KA | PIK3C2B 13/4885PIK3CD 2/4885PIK3CB 4/4885 |
| US-10314845-B2 | Benzimidazole derivatives as PI3 kinase inhibitors | PI4KB, PIK3CD, PI4KA | PIK3C2B 13/4885PIK3CD 2/4885PIK3CB 4/4885 |
| US-20190255064-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | PI4KB, PIK3CD, PI4KA | PIK3C2B 13/4885PIK3CD 2/4885PIK3CB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.